Particle.news
Download on the App Store
19 ARTICLES
·
1h ago

Pfizer to Acquire Metsera for Up to $7.3 Billion to Rebuild Obesity Pipeline

The purchase marks Pfizer's return to obesity drug development following the danuglipron setback.

The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo
FILE - Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10, 2025, in New York. (AP Photo/Yuki Iwamura, File)
Image
Image

Overview

  • Pfizer will pay $47.50 per Metsera share in cash plus up to $22.50 per share in contingent payments tied to clinical and regulatory milestones, valuing the deal at as much as $7.3 billion with an enterprise value of $4.9 billion.
  • Both companies’ boards approved the agreement, which still requires Metsera shareholder and regulatory sign-offs and is expected to close in the fourth quarter of 2025.
  • Metsera adds clinical-stage assets led by MET-097i, a weekly or monthly GLP-1 receptor agonist in Phase II, and MET-233i, a monthly amylin analogue in early trials, along with two oral GLP-1 candidates near first-in-human studies.
  • The contingent value right is linked to starting a Phase III trial of the MET-097i plus MET-233i combination and to potential FDA approval of MET-097i as a monotherapy or in combination.
  • Metsera shares jumped about 60% and Pfizer rose modestly after the announcement, as the deal positions Pfizer to compete with Novo Nordisk and Eli Lilly with programs aimed at less-frequent dosing.